Randomized Trials of Systemic Medically-treated Malignant Mesothelioma: A Systematic Review
2015 (English)In: Anticancer Research, ISSN 0250-7005, E-ISSN 1791-7530, Vol. 35, no 5, 2493-2501 p.Article, review/survey (Refereed) Published
Malignant pleural mesothelioma (MPM) is a rare but aggressive malignancy mainly localized to the pleura. Malignant mesothelioma grows highly invasive into surrounding tissue and has a low tendency to metastasize. The median overall survival (OS) of locally advanced or metastatic disease without treatment is 4-13 months but, during recent years, improvement in survival has been achieved since treatment for patients with mesothelioma has improved with better palliative care, systemic medical treatment, surgery and improved diagnostics methods. The present review aims at describing available data from randomized trials considering systemic medical treatment for this patient category.
Place, publisher, year, edition, pages
2015. Vol. 35, no 5, 2493-2501 p.
Malignant mesothelioma, randomized trials, review
Cancer and Oncology
IdentifiersURN: urn:nbn:se:uu:diva-257356ISI: 000354267200003OAI: oai:DiVA.org:uu-257356DiVA: diva2:839572